AU551039B2 - Amino-1,2,5-thiadiazole derivatives - Google Patents

Amino-1,2,5-thiadiazole derivatives

Info

Publication number
AU551039B2
AU551039B2 AU69822/81A AU6982281A AU551039B2 AU 551039 B2 AU551039 B2 AU 551039B2 AU 69822/81 A AU69822/81 A AU 69822/81A AU 6982281 A AU6982281 A AU 6982281A AU 551039 B2 AU551039 B2 AU 551039B2
Authority
AU
Australia
Prior art keywords
amino
thiadiazole derivatives
thiadiazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
AU69822/81A
Other languages
English (en)
Other versions
AU6982281A (en
Inventor
Joseph S. Amato
John J. Baldwin
William A. Bolhofer
Sandor Karady
William C. Lumma
Leonard M. Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU6982281A publication Critical patent/AU6982281A/en
Application granted granted Critical
Publication of AU551039B2 publication Critical patent/AU551039B2/en
Anticipated expiration legal-status Critical
Withdrawn - After Issue legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU69822/81A 1980-04-30 1981-04-24 Amino-1,2,5-thiadiazole derivatives Withdrawn - After Issue AU551039B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14516280A 1980-04-30 1980-04-30
US14516180A 1980-04-30 1980-04-30
US145162 1980-04-30
US145161 1980-04-30
US23818781A 1981-02-25 1981-02-25
US23977581A 1981-02-25 1981-02-25
US238187 1981-02-25
US239775 1981-02-25

Publications (2)

Publication Number Publication Date
AU6982281A AU6982281A (en) 1981-11-05
AU551039B2 true AU551039B2 (en) 1986-04-17

Family

ID=27495660

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69822/81A Withdrawn - After Issue AU551039B2 (en) 1980-04-30 1981-04-24 Amino-1,2,5-thiadiazole derivatives

Country Status (16)

Country Link
EP (1) EP0040696B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU551039B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1187492A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD201589A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3175201D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK190281A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES501766A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI811328L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR75226B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL62694A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA19134A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO811462L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ196900A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT72926B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO82162A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU111181A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR228941A1 (es) * 1978-04-26 1983-05-13 Glaxo Group Ltd Procedimiento para preparar nuevos derivados de 3,5-diamino-1,2,4-triazol que son activos contra receptores histaminicos
FI76795C (fi) * 1979-09-04 1988-12-12 Bristol Myers Co Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara 3,4-disubstituerade 1,2,5-tiadiazol-1-oxider och -1,1-dioxider samt nya mellanprodukter.
ZA805250B (en) * 1979-09-04 1981-09-30 Bristol Myers Co Chemical compounds
EP0065823A1 (en) * 1981-05-13 1982-12-01 Imperial Chemical Industries Plc Heterocyclic guanidines as histamine H-2 antagonists
EP0073971B1 (en) * 1981-08-24 1986-05-21 Merck & Co. Inc. Thiadiazole oxides as gastric antisecretory agents
US4578471A (en) * 1982-03-29 1986-03-25 Bristol-Myers Company Substituted amino alkyl pyridyl ethanediimidamides
US4517366A (en) * 1982-03-29 1985-05-14 Bristol-Myers Company Intermediates for preparing 3,4-diamino-1,2,5-thiadiazoles
FR2542741B1 (fr) * 1982-03-29 1989-12-08 Bristol Myers Co 3,4-diamino-1,2,5-thiadiazoles substitues possedant une activite antagoniste du recepteur-h2 de l'histamine
US4600779A (en) * 1982-03-29 1986-07-15 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
DK317283A (da) * 1982-07-08 1984-01-09 Glaxo Group Ltd Fremgangsmaade til fremstilling af thiadiazolderivater
US4520025A (en) * 1982-07-21 1985-05-28 William H. Rorer, Inc. Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
JPS5978171A (ja) * 1982-10-26 1984-05-04 Ikeda Mohandou:Kk 複素環式化合物
PT77855B (en) * 1982-12-23 1986-04-16 Smith Kline French Lab Pyridine derivatives
US4461900A (en) * 1983-03-14 1984-07-24 American Home Products Corporation 4,5-Dihydrothiadiazole 1,1-dioxide derivatives
AT387384B (de) * 1983-03-16 1989-01-10 Bristol Myers Co Verfahren zur herstellung von thiadiazolderivaten
US4440933A (en) * 1983-03-16 1984-04-03 Bristol-Myers Company Process for preparing 1,2,5-thiadiazoles
US4529731A (en) * 1983-09-22 1985-07-16 American Home Products Corporation Thiadiazolediamine derivative with histamine H-2 receptor inhibiting properties
US4663347A (en) 1983-10-31 1987-05-05 Merck Frosst Canada, Inc. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
JPS60255756A (ja) * 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
US4692531A (en) * 1984-06-22 1987-09-08 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
US4644006A (en) * 1984-06-22 1987-02-17 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
GB8510680D0 (en) * 1985-04-26 1985-06-05 Smith Kline French Lab Pyridine derivatives
CA1286297C (en) * 1985-06-13 1991-07-16 George S. Sach Pyridine derivatives
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
ATE90076T1 (de) 1986-03-27 1993-06-15 Merck Frosst Canada Inc Tetrahydrocarbazole ester.
GB8610867D0 (en) * 1986-05-02 1986-06-11 Smith Kline French Lab 3-hydroxypyridines
US4829073A (en) * 1988-05-12 1989-05-09 Bristol-Myers Company Thiadiazole oxides for treating gastrointestinal motility disorders
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
HUT61980A (en) 1990-10-12 1993-03-29 Merck Frosst Canada Inc Process for producing saturated hydroxyalkylquinoline acids and pharmaceutical compositions comprising such compounds as active ingredient
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
ATE422203T1 (de) 2002-10-09 2009-02-15 Schering Corp Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
EP1694659B8 (en) 2003-12-19 2008-10-08 Schering Corporation Thiadiazoles as cxc- and cc- chemokine receptor ligands
CN1918156B (zh) 2003-12-22 2010-10-27 先灵公司 作为cxc-和cc-趋化因子受体配体的异噻唑二氧化物
EP1907399B1 (en) 2005-06-29 2010-10-27 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
MX2008000366A (es) 2005-06-29 2008-03-07 Schering Corp Oxadiazoles di-sustituidos como ligandos del receptor cxc-quimiocina.
US20230349922A1 (en) 2020-08-11 2023-11-02 Université De Strasbourg H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1961864A1 (de) * 1969-12-10 1971-06-16 Bayer Ag Derivate des 1-Thia-2,5-diazol-1,1-dioxids
ZA805250B (en) * 1979-09-04 1981-09-30 Bristol Myers Co Chemical compounds
FI76795C (fi) * 1979-09-04 1988-12-12 Bristol Myers Co Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara 3,4-disubstituerade 1,2,5-tiadiazol-1-oxider och -1,1-dioxider samt nya mellanprodukter.

Also Published As

Publication number Publication date
ES511498A0 (es) 1983-02-01
EP0040696A3 (en) 1983-01-26
ES8303383A1 (es) 1983-02-01
ES8303382A1 (es) 1983-02-01
FI811328A7 (fi) 1981-10-31
DD201589A5 (de) 1983-07-27
IL62694A0 (en) 1981-06-29
EP0040696B1 (en) 1986-08-27
RO82162A (ro) 1983-07-07
DE3175201D1 (en) 1986-10-02
RO82162B (ro) 1983-06-30
PT72926B (en) 1983-01-13
PT72926A (en) 1981-05-01
CA1187492A (en) 1985-05-21
ES501766A0 (es) 1983-02-01
FI811328L (fi) 1981-10-31
NZ196900A (en) 1985-01-31
GR75226B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-07-13
DK190281A (da) 1981-10-31
AU6982281A (en) 1981-11-05
YU111181A (en) 1983-10-31
NO811462L (no) 1981-11-02
EP0040696A2 (en) 1981-12-02
MA19134A1 (fr) 1981-12-31

Similar Documents

Publication Publication Date Title
AU551039B2 (en) Amino-1,2,5-thiadiazole derivatives
AU7338081A (en) 1,2,4-triazolylpropenol derivatives
AU563950B2 (en) 2,2 -disubstituted-1,3-oxepine derivatives
AU1666583A (en) 1,2,5-thiadiazole derivatives
AU6494680A (en) 2,3-indoledione derivatives
AU2956484A (en) Benzoxadiazol-4-yl-1,4 dibyropyridine derivatives
AU1575383A (en) 1,4-dihyropyridine derivatives
AU547334B2 (en) 2,4-diaminopyrimidine derivatives
AU544881B2 (en) 3-aryl-5, 6-dihydro-1, 4, 2-oxathiazines
AU8413382A (en) 1,4-piperizine derivatives
AU568295B2 (en) 1,2,4-triazol-i-yl-propionitrile derivatives
AU539995B2 (en) 2,3-dihydro-2,2-dimethylbenzofuran derivatives
AU1741583A (en) 1,4-benzothiazine derivatives
AU535319B2 (en) 1,2,4-imazine derivatives
AU7028081A (en) 5,6-substituted-2-amino benzothiazole derivatives
AU8879882A (en) 1,2,3-thiadiazol-5-yl-urea derivatives
AU7744681A (en) 2,3-dihydro-4-pyrone derivatives
AU572869B2 (en) 1,6-naphthyridin derivatives
AU8879782A (en) 1,2,3-thiadiazol-5-yl-urea derivatives
AU8702182A (en) 1,2-dithiol-3-ylidene ammonium derivatives
AU1974283A (en) 2,3-dihydro-2,2-dimethyl-benzofuran derivatives
AU7906381A (en) Tetrahydro-1,2,4-oxadiazin-5-one derivatives
AU636164B2 (en) 2,3-dihydro-1-hydroxy-3-oxo-2-(1-substituted-4-piperidinyl)- 1N-isoindole derivatives
AU3339584A (en) 1,2,4-triazolylmethyl - pyridyloxymethyl - carbinol derivatives
AU542710B2 (en) 16-amino-17-phenyl-18,19,20-trinor-prosta-glandin derivatives